P. Clark

M. Slevin, P. Clark, 1985, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Filgrastim with dose intensified CDE chemotherapy in small cell lung cancer

P. Clark, N. Thatcher, C. Manegold, 1993 .

Surgical resection with and without chemotherapy in oesophageal cancer

D. Girling, P. Clark, J. Bancewicz, 2002, The Lancet.

The influence of cimetidine on the pharmacokinetics of 5-fluorouracil.

M. Slevin, P. Clark, V. Harvey, 1984, British journal of clinical pharmacology.

126 Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study

J. Carmichael, M. Marangolo, A. Santoro, 1997 .

Small cell lung cancer: single agents revisited.

M. Slevin, P. Clark, 1989, Respiratory medicine.

Randomized trials in the treatment of cancer of the esophagus.

D. Girling, P. Clark, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.

W. Allum, P. Clark, J. Bancewicz, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hypersensitivity and cross-reactivity to cisplatin and analogues

P. Clark, J. Green, A. Shlebak, 1995, Cancer Chemotherapy and Pharmacology.

Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study

P. Clark, D. Smith, H. Innes, 2003, British Journal of Cancer.

Chemotherapy for stomach cancer.

M. Slevin, P. Clark, 1987, British medical journal.

Successful treatment of a primary endodermal sinus tumor of the liver

P. Clark, R. A. Owen, W. Stebbings, 1992, Cancer.

Predicting etoposide toxicity: relationship to organ function and protein binding.

M. Slevin, P. Clark, S. Joel, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.

D G Lowe, R. Reznek, W. Gregory, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.

D. Dunlop, J. von Pawel, U. Gatzemeier, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (Trial 1) and in combination with 5-fluorouracil (Trial 2) in advanced colorectal cancer

H. Blomgren, R. Reznek, P. Clark, 1987, International Journal of Colorectal Disease.

The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer.

P. Clark, B. Cottier, 1992, Seminars in oncology.

Continuing Clozapine Despite Neutropenia

P. Clark, D. Finnegan, M. Wesson, 1996, British Journal of Psychiatry.

Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives.

P. Clark, 1992, Seminars in oncology.

Myeloma during a decade: clinical experience in a single centre.

W. Gregory, P. Clark, S. Love, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Pronounced and prolonged ST segment elevation: a pathognomonic sign of tumor invasion of the heart.

P. Clark, P. Schulman, R. B. Hartman, 1982, Archives of internal medicine.

Topotecan (Hycamtin™) in small cell lung cancer (SCLC) after failure of first line therapy: Multicentre phase II study

J. Carmichael, M. Marangolo, A. Santoro, 1997 .

Current Role of Oral Etoposide in the Management of Small Cell Lung Cancer

P. Clark, 2012, Drugs.

Increasing the dose intensity of chemotherapy by means of granulocyte-colony stimulating factor (G-CSF) support in the treatment of small cell lung cancer (SCLC)

R. Stephens, D. Girling, P. Clark, 1996, European journal of cancer.

Stability of the i.v. and oral formulations of etoposide in solution

S. Joel, M. Slevin, P. Clark, 2004, Cancer Chemotherapy and Pharmacology.

Oral urea in the treatment of secondary tumours in the liver.

M. Slevin, P. Clark, R. Osborne, 1988, British Journal of Cancer.

High-dose cytarabine in small cell lung cancer.

M. Slevin, P. Clark, R. Osborne, 1987, Cancer treatment reports.

Theinfluence ofcimetidine onthepharmacokinetics of 5-fluorouracil

M. Slevin, P. Clark, V. Harvey, 1984 .